Cancer,Cured, for Good! but......

[Guest guest]

Cancer Cured For GoodBy Bill Sardi and Hubbell October 2008 It works 100% of the time to eradicate cancer completely, and cancer does not recur even years later. That is how researchers describe the most convincing cancer cure ever announced. The weekly injection of just 100 billionths of a gram of a harmless glyco-protein (a naturally-produced molecule with a sugar component and a protein component) activates the human immune system and cures cancer for good, according to human studies among breast cancer and colon cancer patients, producing complete remissions lasting 4 and 7 years respectively. This glyco-protein cure is totally without side effect but currently goes unused by cancer doctors. Normal Gc protein (also called Vitamin-D binding protein) , an abundant

glyco-protein found in human blood serum, becomes the molecular switch to activate macrophages when it is converted to its active form, called Gc macrophage activating factor (Gc-MAF). Gc protein is normally activated by conversion to Gc-MAF with the help of the B and T cells (bone marrow-made and thymus gland-made white blood cells). But, as researchers explain it themselves, cancer cells secrete an enzyme known as alpha-N-acetylgalac tosaminidase (also called Nagalase) that completely blocks conversion of Gc protein to Gc-MAF, preventing tumor-cell killing by the macrophages. This is the way cancer cells escape detection and destruction, by disengaging the human immune system. This also leaves cancer patients prone to infections and many then succumb to pneumonia or other infections. The once-weekly injection of minute amounts of Gc-MAF, just 100 nanograms (billionths of a gram), activates

macrophages and allows the immune system to pursue cancer cells with vigor, sufficient to produce total long-term cures in humans. Nobuto Yamamoto, director of the Division of Cancer Immunology and Molecular Biology, Socrates Institute for Therapeutic Immunology, Philadelphia, Pennsylvania, says this is "probably the most potent macrophage activating factor ever discovered." A MACROPHAGE OVERCOMES AND EATS A CANCER CELL. FROM THE UPJOHN COMPANY, THE IMMUNE SYSTEM Once a sufficient number of activated macrophages are produced, another Gc-MAF injection is not needed for a week because macrophages have a half-life of about six days. After 16-22 weekly doses of Gc-MAF the amount of Nagalase enzyme fell to levels found in healthy people, which serves as evidence tumors have been completely eliminated. The treatment was fool-proof - - - it worked in 100% of 16 breast cancer patients and

there were no recurrent tumors over a period of 4 years, says a report in the January 15 issue of the International Journal of Cancer. [international Journal Cancer.2008 January15; 122(2):461-7] In another startling follow-up report by Dr. Yamamoto and colleagues, published in the upcoming July issue of Cancer Immunology Immunotherapy, Gc-MAF therapy totally abolished tumors in 8 colon cancer patients who had already undergone surgery but still exhibited circulating cancer cells (metastases) . After 32-50 weekly injections, "all colorectal cancer patients exhibited healthy control levels of the serum Nagalase activity, indicating eradication of metastatic tumor cells,"said researchers, an effect that lasted 7 years with no indication of cancer recurrence either by enzyme activity or CT scans, said researchers. [Cancer Immunology, Immunotherapy Volume 57, Number 7 / July 2008] Published in an

early online edition of this journal, this confirming report has received no attention by the new media so far, despite its striking importance. Gc-MAF treatment for cancer has been agonizingly slow to develop. Dr. Yamamoto first described this immuno-therapy in 1993. [The Journal of Immunology, 1993 151 (5); 2794-2802] In a similar animal experiment published in 2003, researchers in Germany, Japan and the United States collaborated to successfully demonstrate that after they had injected macrophage activating factor (Gc-MAF) into tumor-bearing mice, it totally eradicated tumors. [Neoplasia 2003 January; 5(1): 32–40] In 1997 Dr. Yamamoto injected GcMAF protein into tumor-bearing mice, with the same startling results. A single enzyme injection doubled the survival of these mice and just four enzyme injections increased survival by 6-fold. [Cancer Research 1997 Jun 1; 57(11):2187-

92] In 1996 Dr. Yamamoto reported that all 52 cancer patients he had studied carried elevated blood plasma levels of the immune inactivating alpha-N-acetylgalac tosaminidase enzyme (Nagalase), whereas healthy humans had very low levels of this enzyme. [Cancer Research 1996 Jun 15; 56(12):2827- 31] In the early 1990s, Dr. Yamamoto first described how the human immune system is disengaged by enzymes secreted from cancer cells, even filing a patent on the proposed therapy. [uS Patent 5326749, July 1994; Cancer Research 1996 June 15; 56: 2827-31] Activated Gc protein has been used in humans at much higher doses without side effect. This Gc macrophage activating factor (Gc-MAF) has been shown to be effective against a variety of cancers including breast, prostate, stomach, liver, lung, uterus, ovary, brain, skin, head/neck cancer, and leukemia. Although GcMAF is also called Vitamin-D

binding protein, the activation of macrophages does not require Vitamin D. It cannot be said the Gc-MAF cancer cure has gone unheralded. Reuters News covered this developing story in January. But the news story still did not receive top billing nor did it fully elucidate the importance of the discovery, actually made years ago, that the human body is capable of abolishing cancer once its immune system is properly activated. GcMAF is a naturally made molecule and is not patentable, though its manufacturing process is patent protected. There is no evidence of any current effort to commercialize this therapy or put it into practice. Should such an effective treatment for cancer come into common practice, the income stream from health-insurance plans for every oncology office and cancer center in the world Would likely be reduced to the point of financial insolvency and hundreds of

thousands of jobs would be eliminated. The National Cancer Institute estimates cancer care in the U.S. costs ~$72 billion annually (2004). Furthermore, about $55 billion of cancer drugs are used annually, none which have not significantly improved survival rates throughout the history of their use. If a typical cancer patient had to undergo 30 GcMAF injections at a cost of $150 per injection, that would cost ~$4500, not counting doctor's office visits and follow-up testing. For comparison, gene-targeted cancer drugs range from $13,000 to $100,000 in cost per year and produce only marginal improvements in survival (weeks to months). [Targeted Oncology 2007 April, 2 (2); 113-19] Up to this point, the National Cancer Institute is totally silent on this discovery and there is no evidence the cancer care industry plans to quickly mobilize to use this otherwise harmless treatment.

Addendum: Sadly, the treatment you have just read about is not available anywhere. Its inventor is attempting to patent a version of it to profiteer off of it even though there is no need to improve upon the GcMAF molecule - - it worked without failure to completely cure four different types of cancer with no long-term remissions and without side effect. While GcMAF is produced by every healthy adult, there are no centers available to extract it from blood samples and inject it into patients with malignancies. Hopefully, someday, doctors will write protocols to do this and submit them to institutional review boards so GcMAF treatment can be performed on an experimental basis. GcMAF is a naturally-made molecule that cannot be patented. This article was written to reveal that there are proven cancer cures that go unused. Of interest, not one oncologist

has requested information about GcMAF since this article was written, while I have been barraged with inquires from cancer patients, their families and some interested physicians who are not cancer doctors. -Bill Sardi HERE IS THE ABSTRACT TO THE ABOVE ARTICLEInternational Journal of Cancer. [international Journal Cancer.2008 January15; 122(2):461-7] Pages 461 – 467 Published Online: 12 Oct 2007 UICC International Union Against CancerCancer TherapyImmunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF)Nobuto Yamamoto 1 *, Hirofumi Suyama 2, Nobuyuki Yamamoto 1, Naofumi Ushijima 11Division of Cancer Immunology and Molecular Biology, Socrates Institute for Therapeutic Immunology, Philadelphia, PA 19126-33052Nagasaki Immunotherapy Research Group, Nagasaki, Japan

850-806email: Nobuto Yamamoto (nobutoyamaverizon (DOT) net)*Correspondence to Nobuto Yamamoto, Division of Cancer and Molecular Immunology, Socrates Institute for Therapeutic Immunology, 1040 66th Ave, Philadelphia, PA 19126-3305, USAFax: +215-424-1850Funded by:US Public Health Service; Grant Number: AI-32140Elsa U. Pardee FoundationKeywordsmacrophage activating factor • tumoricidal • immunotherapy • deglycosylation • -N-acetylgalactosam inidaseAbstractSerum vitamin D3-binding protein (Gc protein) is the precursor for the principal macrophage activating factor (MAF). The MAF precursor activity of serum Gc protein of breast cancer patients was lost or reduced because

Gc protein was deglycosylated by serum -N-acetylgalactosamini dase (Nagalase) secreted from cancerous cells. Patient serum Nagalase activity is proportional to tumor burden. The deglycosylated Gc protein cannot be converted to MAF, resulting in no macrophage activation and immunosuppression. Stepwise incubation of purified Gc protein with immobilized r=0 DATASIZE="843" ID="9" SRC="aoladp://MA19848716 -0024/image005. gif">-galactosidase and sialidase generated probably the most potent macrophage activating factor (termed GcMAF) ever discovered, which produces no adverse effect in humans. Macrophages treated in vitro with GcMAF (100 pg/ml) are highly tumoricidal to mammary adenocarcinomas. Efficacy of GcMAF for treatment of metastatic breast cancer was investigated with 16 nonanemic patients who received weekly administration of GcMAF (100 ng). As GcMAF

therapy progresses, the MAF precursor activity of patient Gc protein increased with a concomitant decrease in serum Nagalase. Because of proportionality of serum Nagalase activity to tumor burden, the time course progress of GcMAF therapy was assessed by serum Nagalase activity as a prognostic index. These patients had the initial Nagalase activities ranging from 2.32 to 6.28 nmole/min/mg protein. After about 16-22 administrations (approximately 3.5-5 months) of GcMAF, these patients had insignificantly low serum enzyme levels equivalent to healthy control enzyme levels, ranging from 0.38 to 0.63 nmole/min/mg protein, indicating eradication of the tumors. This therapeutic procedure resulted in no recurrence for more than 4 years. © 2007 Wiley-Liss, Inc.

[Guest guest]

Too many people would lose out on ALOT of money if they cured cancer. Doctors love things like chemo and cancer drugs and whatnot because its maintenance and with that comes more money. If you cure cancer all together, you dont need to go back for all the drugs, appointments, chemo, etc... its in their best interest that you stay sick, because sick people equal more money. They work on ways and drugs to help, but never cure it for good. Even when you go into "remission" they know good and well that more likely than not you will be sick again so that means more money for doctors, drug companies, research centers and so on. Until the world is put into a position where actually caring for each other is our only priority and way to survive, we wont see a cure, just very expensive band-aids.

From: mark seebach <mach54nm@...>Subject: [] Cancer,Cured, for Good! but......"humanity healing" < >Date: Tuesday, December 9, 2008, 3:33 PM

Cancer Cured For GoodBy Bill Sardi and Hubbell October 2008 It works 100% of the time to eradicate cancer completely, and cancer does not recur even years later. That is how researchers describe the most convincing cancer cure ever announced. The weekly injection of just 100 billionths of a gram of a harmless glyco-protein (a naturally-produced molecule with a sugar component and a protein component) activates the human immune system and cures cancer for good, according to human studies among breast cancer and colon cancer patients, producing complete remissions lasting 4 and 7 years respectively. This glyco-protein cure is totally without side effect but currently goes unused by cancer doctors. Normal Gc protein (also called Vitamin-D binding protein) , an abundant glyco-protein found in human blood serum, becomes the molecular switch to activate

macrophages when it is converted to its active form, called Gc macrophage activating factor (Gc-MAF). Gc protein is normally activated by conversion to Gc-MAF with the help of the B and T cells (bone marrow-made and thymus gland-made white blood cells). But, as researchers explain it themselves, cancer cells secrete an enzyme known as alpha-N-acetylgalac tosaminidase (also called Nagalase) that completely blocks conversion of Gc protein to Gc-MAF, preventing tumor-cell killing by the macrophages. This is the way cancer cells escape detection and destruction, by disengaging the human immune system. This also leaves cancer patients prone to infections and many then succumb to pneumonia or other infections. The once-weekly injection of minute amounts of Gc-MAF, just 100 nanograms (billionths of a gram), activates macrophages and allows the immune system to pursue cancer cells with vigor, sufficient to

produce total long-term cures in humans. Nobuto Yamamoto, director of the Division of Cancer Immunology and Molecular Biology, Socrates Institute for Therapeutic Immunology, Philadelphia, Pennsylvania, says this is "probably the most potent macrophage activating factor ever discovered." A MACROPHAGE OVERCOMES AND EATS A CANCER CELL. FROM THE UPJOHN COMPANY, THE IMMUNE SYSTEM Once a sufficient number of activated macrophages are produced, another Gc-MAF injection is not needed for a week because macrophages have a half-life of about six days. After 16-22 weekly doses of Gc-MAF the amount of Nagalase enzyme fell to levels found in healthy people, which serves as evidence tumors have been completely eliminated. The treatment was fool-proof - - - it worked in 100% of 16 breast cancer patients and there were no recurrent tumors over a period of 4 years, says a report in the January 15

issue of the International Journal of Cancer. [international Journal Cancer.2008 January15; 122(2):461-7] In another startling follow-up report by Dr. Yamamoto and colleagues, published in the upcoming July issue of Cancer Immunology Immunotherapy, Gc-MAF therapy totally abolished tumors in 8 colon cancer patients who had already undergone surgery but still exhibited circulating cancer cells (metastases) . After 32-50 weekly injections, "all colorectal cancer patients exhibited healthy control levels of the serum Nagalase activity, indicating eradication of metastatic tumor cells,"said researchers, an effect that lasted 7 years with no indication of cancer recurrence either by enzyme activity or CT scans, said researchers. [Cancer Immunology, Immunotherapy Volume 57, Number 7 / July 2008] Published in an early online edition of this journal, this confirming report has received no attention

by the new media so far, despite its striking importance. Gc-MAF treatment for cancer has been agonizingly slow to develop. Dr. Yamamoto first described this immuno-therapy in 1993. [The Journal of Immunology, 1993 151 (5); 2794-2802] In a similar animal experiment published in 2003, researchers in Germany, Japan and the United States collaborated to successfully demonstrate that after they had injected macrophage activating factor (Gc-MAF) into tumor-bearing mice, it totally eradicated tumors. [Neoplasia 2003 January; 5(1): 32–40] In 1997 Dr. Yamamoto injected GcMAF protein into tumor-bearing mice, with the same startling results. A single enzyme injection doubled the survival of these mice and just four enzyme injections increased survival by 6-fold. [Cancer Research 1997 Jun 1; 57(11):2187- 92] In 1996 Dr. Yamamoto reported that all 52 cancer patients he had studied carried

elevated blood plasma levels of the immune inactivating alpha-N-acetylgalac tosaminidase enzyme (Nagalase), whereas healthy humans had very low levels of this enzyme. [Cancer Research 1996 Jun 15; 56(12):2827- 31] In the early 1990s, Dr. Yamamoto first described how the human immune system is disengaged by enzymes secreted from cancer cells, even filing a patent on the proposed therapy. [uS Patent 5326749, July 1994; Cancer Research 1996 June 15; 56: 2827-31] Activated Gc protein has been used in humans at much higher doses without side effect. This Gc macrophage activating factor (Gc-MAF) has been shown to be effective against a variety of cancers including breast, prostate, stomach, liver, lung, uterus, ovary, brain, skin, head/neck cancer, and leukemia. Although GcMAF is also called Vitamin-D binding protein, the activation of macrophages does not require Vitamin D. It cannot

be said the Gc-MAF cancer cure has gone unheralded. Reuters News covered this developing story in January. But the news story still did not receive top billing nor did it fully elucidate the importance of the discovery, actually made years ago, that the human body is capable of abolishing cancer once its immune system is properly activated. GcMAF is a naturally made molecule and is not patentable, though its manufacturing process is patent protected. There is no evidence of any current effort to commercialize this therapy or put it into practice. Should such an effective treatment for cancer come into common practice, the income stream from health-insurance plans for every oncology office and cancer center in the world Would likely be reduced to the point of financial insolvency and hundreds of thousands of jobs would be eliminated. The National Cancer Institute estimates cancer care in the

U.S. costs ~$72 billion annually (2004). Furthermore, about $55 billion of cancer drugs are used annually, none which have not significantly improved survival rates throughout the history of their use. If a typical cancer patient had to undergo 30 GcMAF injections at a cost of $150 per injection, that would cost ~$4500, not counting doctor's office visits and follow-up testing. For comparison, gene-targeted cancer drugs range from $13,000 to $100,000 in cost per year and produce only marginal improvements in survival (weeks to months). [Targeted Oncology 2007 April, 2 (2); 113-19] Up to this point, the National Cancer Institute is totally silent on this discovery and there is no evidence the cancer care industry plans to quickly mobilize to use this otherwise harmless treatment. Addendum: Sadly, the treatment you have just read about is not available anywhere. Its inventor

is attempting to patent a version of it to profiteer off of it even though there is no need to improve upon the GcMAF molecule - - it worked without failure to completely cure four different types of cancer with no long-term remissions and without side effect. While GcMAF is produced by every healthy adult, there are no centers available to extract it from blood samples and inject it into patients with malignancies. Hopefully, someday, doctors will write protocols to do this and submit them to institutional review boards so GcMAF treatment can be performed on an experimental basis. GcMAF is a naturally-made molecule that cannot be patented. This article was written to reveal that there are proven cancer cures that go unused. Of interest, not one oncologist has requested information about GcMAF since this article was written, while I have been barraged with inquires from

cancer patients, their families and some interested physicians who are not cancer doctors. -Bill Sardi HERE IS THE ABSTRACT TO THE ABOVE ARTICLEInternational Journal of Cancer. [international Journal Cancer.2008 January15; 122(2):461-7] Pages 461 – 467 Published Online: 12 Oct 2007 UICC International Union Against CancerCancer TherapyImmunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF)Nobuto Yamamoto 1 *, Hirofumi Suyama 2, Nobuyuki Yamamoto 1, Naofumi Ushijima 11Division of Cancer Immunology and Molecular Biology, Socrates Institute for Therapeutic Immunology, Philadelphia, PA 19126-33052Nagasaki Immunotherapy Research Group, Nagasaki, Japan 850-806email: Nobuto Yamamoto (nobutoyamaverizon (DOT) net)*Correspondence to Nobuto Yamamoto, Division of Cancer and Molecular Immunology, Socrates Institute for Therapeutic Immunology, 1040 66th Ave, Philadelphia, PA 19126-3305, USAFax: +215-424-1850Funded by:US Public Health Service; Grant Number: AI-32140Elsa U. Pardee FoundationKeywordsmacrophage activating factor • tumoricidal • immunotherapy • deglycosylation • -N-acetylgalactosam inidaseAbstractSerum vitamin D3-binding protein (Gc protein) is the precursor for the principal macrophage activating factor (MAF). The MAF precursor activity of serum Gc protein of breast cancer patients was lost or reduced because Gc protein was deglycosylated by serum -N-acetylgalactosamini dase (Nagalase) secreted from cancerous cells. Patient serum Nagalase activity is

proportional to tumor burden. The deglycosylated Gc protein cannot be converted to MAF, resulting in no macrophage activation and immunosuppression. Stepwise incubation of purified Gc protein with immobilized r=0 DATASIZE="843" ID="9" SRC="aoladp://MA19848716 -0024/image005. gif">-galactosidase and sialidase generated probably the most potent macrophage activating factor (termed GcMAF) ever discovered, which produces no adverse effect in humans. Macrophages treated in vitro with GcMAF (100 pg/ml) are highly tumoricidal to mammary adenocarcinomas. Efficacy of GcMAF for treatment of metastatic breast cancer was investigated with 16 nonanemic patients who received weekly administration of GcMAF (100 ng). As GcMAF therapy progresses, the MAF precursor activity of patient Gc protein increased with a concomitant decrease in serum Nagalase. Because of

proportionality of serum Nagalase activity to tumor burden, the time course progress of GcMAF therapy was assessed by serum Nagalase activity as a prognostic index. These patients had the initial Nagalase activities ranging from 2.32 to 6.28 nmole/min/mg protein. After about 16-22 administrations (approximately 3.5-5 months) of GcMAF, these patients had insignificantly low serum enzyme levels equivalent to healthy control enzyme levels, ranging from 0.38 to 0.63 nmole/min/mg protein, indicating eradication of the tumors. This therapeutic procedure resulted in no recurrence for more than 4 years. © 2007 Wiley-Liss, Inc.